The Cochlear share price has shaved 13% from its all-time high. Is now the time to pounce?

Cochlear has jumped more than $30 per share in the last 2 months.

| More on:
cochlear happy, share price rise, up, increase

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Cochlear shares extend gains today as investors continue bidding up prices 
  • After a robust half, analysts are more constructive but there's still a fairly even view of Cochlear's next moves 
  • In the last 12 months, the Cochlear share price has jumped around 1% into the green after a period of rough volatility 

Shares of Cochlear Limited (ASX: COH) are inching forward on Thursday to trade 56 basis points higher at $225.98.

After a swift recovery in March, where shares thrust off a bottom of $190 – from $182 in January as well – Cochlear is now trading 4% higher this year.

TradingView Chart

Is Cochlear a buy?

Analysts have turned more constructive on the company since it released its first half results earlier this year.

Since then, the number of brokers advocating to buy Cochlear has surged to 42%, in line with the percentage of holds.

Still, almost 16% of coverage reckons to sell the stock right now, with RBC Capital Markets pricing a $149 per share valuation on Cochlear.

However, despite the balanced view, Cochlear is trading above its consensus price target of $221.18 apiece.

Analysts at JP Morgan were clearly impressed by the company's latest earnings, noting the "strong result signals [its] growth story [is] clearly intact," in a recent note.

"Cochlear reported a strong first half as European and emerging market implant volumes recovered, despite headwinds from multiple COVID waves," it said.

"The result was also supported by a sharp lift in Services revenue as upgrades lifted as well as very strong Acoustic sales growth. This result signals the recovery is now broad-based, with the pandemic headwinds now manageable confirming the resilience of the growth story," the broker added.

Given its performance, JP Morgan has now dampened its concerns surrounding the maker and researcher of cochlear implant systems.

However, valuation remains a concern, and with some foreseeable challenges ahead, the broker is comfortable on the sidelines at a neutral rating.

"Cochlear's key markets have recovered more rapidly than we had feared given this results strong beat…we think the company is well positioned to return to its strong historical growth profile," it noted.

"While the medium-term outlook remains compelling with the stock trading at its 5 year average [price to earnings] P/E and with limited upside to our DCF-based price target, we have retained our neutral rating (June 2022 price target lifted to $223 from $207)."

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »